Auximines Clinical Solutions SRL
Auximines Clinical Solutions reported total assets of 226,257 € at the end of the 2025 financial year (annual accounts filed with the NBB on 17 Jul 2026).
The score of Auximines Clinical Solutions shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -4 % Total assets +7 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Auximines Clinical Solutions's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 55,415 € | ||||
| Equity | 182,677 € | ||||
| Cash | 38,187 € | ||||
| EBITDA | 84,189 € | ||||
| Total assets | 226,257 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 17 Jul 2026
- Year ended 31 Dec 2024filed on 13 Jun 2025
- Year ended 31 Dec 2023filed on 17 Jun 2024
- Year ended 31 Dec 2022filed on 20 Jun 2023
- Year ended 31 Dec 2021filed on 22 Jul 2022
Auximines Clinical Solutions's financial analysis
- Solvency80.7%sector median: 55.6%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Auximines Clinical Solutions
Auximines Clinical Solutions's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0669.694.136
- VAT number
- BE0669694136
- Peppol
- Registered · 0208:0669694136 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 17 Jan 2017
- Registered office
- 1981 Zemst
- Latest accounts
- 2025 · filed on 17 Jul 2026
- Activity
- Activities of holding companies (NACE 64210)
Auximines Clinical Solutions (SRL) has been based in Zemst since 2017, active in: activities of holding companies. For 2025, it reports a net profit of 55,415 € and equity of 182,677 €; its revenue is not published. Its solvency stands at 80.7%, above the median of its sector (55.6%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Auximines Clinical Solutions
Companies in the same business, of comparable size and area, outside its group.
- Bromo Activities of holding companies Hasselt · balance sheet 218,536 €
- van PUIJENBROEK MANAGEMENT Activities of holding companies Beersel · balance sheet 179,001 €
- WB Beheer Activities of holding companies Antwerp · balance sheet 11,510 €
- Chamagg Activities of holding companies Hasselt · balance sheet 256,738 €
- Tipsy Wipsy Activities of holding companies Leuven · balance sheet 222,872 €
- RCON Activities of holding companies Diest · balance sheet 230,007 €
- Unfolds Activities of holding companies Diksmuide · balance sheet 221,213 €
- Bioresolutions Activities of holding companies Zulte · balance sheet 219,616 €
Frequently asked questions about Auximines Clinical Solutions
What is the revenue of Auximines Clinical Solutions?
Auximines Clinical Solutions files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Auximines Clinical Solutions?
In Belgium, the VAT number is the company number prefixed with BE: BE0669694136 for Auximines Clinical Solutions, if the company is VAT-registered. Its company number (CBE) is 0669.694.136.
Where is the registered office of Auximines Clinical Solutions?
According to the CBE register, the registered office of Auximines Clinical Solutions is in 1981 Zemst.
What is the equity of Auximines Clinical Solutions?
At the close of the 2025 financial year, the equity of Auximines Clinical Solutions amounts to 182,677 €, a solvency of 80.7% of total assets.
Who manages Auximines Clinical Solutions?
The register lists 2 active mandates at Auximines Clinical Solutions. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Auximines Clinical Solutions
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →